Definium Therapeutics Q2 net loss widens on higher warrant costs
Definium Therapeutics Q2 net loss widens on higher warrant costs
Overview
US biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expenses
Company raised $805 mln in public offering, increasing cash to $1.1 bln at quarter end
Announced positive Phase 3 results for lead candidate in major depressive disorder
Outlook
Company expects topline data from Phase 3 Voyage study (GAD) week of August 10, 2026
Topline results from Phase 3 Panorama study (GAD) anticipated in September 2026
Company expects current cash and investments to fund operations into 2030
Result Drivers
R&D SPENDING - Higher research and development expenses were mainly due to increased costs for the DT120 program and expanded personnel, according to the company
G&A EXPENSES - General and administrative expenses rose due to higher stock-based compensation, corporate and government affairs, personnel, and commercial-preparedness costs
WARRANT LIABILITIES - Net loss was significantly affected by a non-cash increase in the fair value of warrant liabilities due to share price appreciation
Company press release: ID:nBwmgHBVa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $1.44 |
|
Q2 Net Loss |
| $158.99 mln |
|
Q2 Income from Operations |
| -$75.08 mln |
|
Q2 Operating Expenses |
| $75.08 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Definium Therapeutics Inc is $59.00, about 32.9% above its August 5 closing price of $44.39
Reuters Recommended Reads
Aug 6 - Precision BioSciences Q2 net loss widens on warrant liability charge
Aug 6 - Praxis Precision Q2 net loss widens on higher expenses
Aug 6 - vTv Therapeutics Q2 net loss widens on higher trial costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)